Akebia Therapeutics Files 2025 Proxy Statement
Ticker: AKBA · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1517022
| Field | Detail |
|---|---|
| Company | Akebia Therapeutics, Inc. (AKBA) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
Related Tickers: AKBA
TL;DR
Akebia's proxy statement is out, detailing exec pay for 2024. Vote on proposals soon.
AI Summary
Akebia Therapeutics, Inc. filed its DEF 14A on April 29, 2025, detailing executive compensation and corporate governance. The filing includes information on the compensation of key executives such as John P. Butler, Ellen E. Snow, Steven K. Burke, Nicholas P. Grund, and Michel Dahan for the fiscal year ending December 31, 2024. It also provides comparative compensation data for previous fiscal years.
Why It Matters
This filing provides shareholders with crucial information regarding executive compensation and corporate governance practices, enabling informed voting decisions on proposals presented at the annual meeting.
Risk Assessment
Risk Level: low — This filing is a routine annual disclosure and does not present new material risks.
Key Numbers
- 2024-12-31 — Fiscal Year End (Executive compensation reporting period)
- 20250429 — Filing Date (Date of DEF 14A submission)
Key Players & Entities
- Akebia Therapeutics, Inc. (company) — Filer
- John P. Butler (person) — Member
- Ellen E. Snow (person) — Member
- Steven K. Burke (person) — Member
- Nicholas P. Grund (person) — Member
- Michel Dahan (person) — Member
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide shareholders with information regarding executive compensation, corporate governance, and proposals to be voted on at the company's annual meeting.
Which fiscal year's executive compensation is detailed in this filing?
This filing details executive compensation for the fiscal year ending December 31, 2024.
Who are some of the named individuals whose compensation is discussed?
Some of the named individuals whose compensation is discussed include John P. Butler, Ellen E. Snow, Steven K. Burke, Nicholas P. Grund, and Michel Dahan.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 29, 2025.
What is the Standard Industrial Classification (SIC) code for Akebia Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Akebia Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 by John P. Butler regarding Akebia Therapeutics, Inc. (AKBA).